Literature DB >> 9530884

DNA content and other factors associated with ten-year survival after resection of pancreatic carcinoma.

D C Allison1, S Piantadosi, R H Hruban, W C Dooley, E K Fishman, C J Yeo, K D Lillemoe, H A Pitt, P Lin, J L Cameron.   

Abstract

BACKGROUND AND OBJECTIVES: The 5-year survival rates after resection of pancreatic carcinoma have recently increased and are predicted by tumor size, DNA content, and lymph node metastases at the time of resection. However, whether the 10-year survival rates have also increased and are similarly predicted by these factors is not known.
METHODS: The influence of preoperative imaging tests, alcohol consumption, cigarette smoking, K-ras mutations, anatomic location, details of surgical resection, pathologic findings, and tumor DNA content on survival was tested for 96 patients after a successful resection of a pancreatic carcinoma with 17 patients being followed for more than 5 years.
RESULTS: The 5- and 10-year patient survival rates were 18% and 3%, respectively. Univariate and multivariable analyses showed that tumor DNA content, pathologic tumor size, and lymph node metastases were the strongest prognostic indicators for long-term patient survival, although the importance of tumor size may diminish 2 or more years after resection. Surprisingly, the 11 patients with diploid carcinomas > or = 4 cm had an estimated 10-year survival rate of 36%.
CONCLUSION: These results show that the 10-year survival rate for pancreatic carcinoma remains very low, although the subset of patients with biologically favorable tumors has a prolonged survival and possible cure after resection.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9530884     DOI: 10.1002/(sici)1096-9098(199803)67:3<151::aid-jso2>3.0.co;2-8

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  42 in total

1.  Periampullary adenocarcinoma: analysis of 5-year survivors.

Authors:  B Gudjonsson
Journal:  Ann Surg       Date:  1999-11       Impact factor: 12.969

2.  The ARF tumor suppressor inhibits tumor cell colonization independent of p53 in a novel mouse model of pancreatic ductal adenocarcinoma metastasis.

Authors:  Viviane Palhares Muniz; J Matthew Barnes; Seema Paliwal; Xuefeng Zhang; Xiaoyun Tang; Songhai Chen; Kokou D Zamba; Joseph J Cullen; David K Meyerholz; Shari Meyers; J Nathan Davis; Steven R Grossman; Michael D Henry; Dawn E Quelle
Journal:  Mol Cancer Res       Date:  2011-06-02       Impact factor: 5.852

Review 3.  Pancreatic cancer: from genes to patient care.

Authors:  R H Hruban
Journal:  J Gastrointest Surg       Date:  2001 Nov-Dec       Impact factor: 3.452

4.  Pancreatic adenocarcinoma.

Authors:  Margaret A Tempero; J Pablo Arnoletti; Stephen Behrman; Edgar Ben-Josef; Al B Benson; Jordan D Berlin; John L Cameron; Ephraim S Casper; Steven J Cohen; Michelle Duff; Joshua D I Ellenhorn; William G Hawkins; John P Hoffman; Boris W Kuvshinoff; Mokenge P Malafa; Peter Muscarella; Eric K Nakakura; Aaron R Sasson; Sarah P Thayer; Douglas S Tyler; Robert S Warren; Samuel Whiting; Christopher Willett; Robert A Wolff
Journal:  J Natl Compr Canc Netw       Date:  2010-09       Impact factor: 11.908

5.  Changes in connexin43 expression and localization during pancreatic cancer progression.

Authors:  Joell L Solan; Sunil R Hingorani; Paul D Lampe
Journal:  J Membr Biol       Date:  2012-06-23       Impact factor: 1.843

Review 6.  Borderline resectable pancreatic cancer: definitions and management.

Authors:  Nicole E Lopez; Cristina Prendergast; Andrew M Lowy
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

7.  Mode of spread in the early phase of lymphatic metastasis in pancreatic ductal adenocarcinoma: prognostic significance of nodal microinvolvement.

Authors:  Dean Bogoevski; Emre F Yekebas; Paulus Schurr; Jussuf T Kaifi; Asad Kutup; Andreas Erbersdobler; Klaus Pantel; Jakob R Izbicki
Journal:  Ann Surg       Date:  2004-12       Impact factor: 12.969

Review 8.  Trials of gene therapy for pancreatic carcinoma.

Authors:  Christopher M Halloran; Paula Ghaneh; Eithne Costello; John P Neoptolemos
Journal:  Curr Gastroenterol Rep       Date:  2005-06

9.  Strong prognostic value of nodal and bone marrow micro-involvement in patients with pancreatic ductal carcinoma receiving no adjuvant chemotherapy.

Authors:  Emre-F Yekebas; Dean Bogoevski; Michael Bubenheim; Björn-Christian Link; Jussuf-T Kaifi; Robin Wachowiak; Oliver Mann; Asad Kutup; Guellue Cataldegirmen; Lars Wolfram; Andreas Erbersdobler; Christoph Klein; Klaus Pantel; Jakob-R Izbicki
Journal:  World J Gastroenterol       Date:  2006-10-28       Impact factor: 5.742

10.  Clinical and pathologic prognostic factors for curative resection for pancreatic cancer.

Authors:  M V Perini; A L Montagnini; J Jukemura; S Penteado; E E Abdo; R Patzina; I Cecconello; J E M Cunha
Journal:  HPB (Oxford)       Date:  2008       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.